Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in Patients With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Summary

3/30/2021 Note: Trial is close to meeting enrollment; please contact site. The purpose of this phase II study is to investigate if nivolumab given with tadalafil and vancomycin causes liver cancer to shrink.

General Information

NCT#: NCT03785210
Study ID: 190033
Trial Phase: Phase II

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Tadalafil, Nivolumab, Vancomycin

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search